NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance

Sorafenib, an oral multikinase inhibitor, is the only approved agent for the treatment of advanced hepatocellular carcinoma (HCC). However, its benefits are modest, and as its mechanisms of action remain elusive, a better understanding of its anticancer effects is needed. Based on our previous study...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cell Death Dis
Glavni autori: Emma, M R, Iovanna, J L, Bachvarov, D, Puleio, R, Loria, G R, Augello, G, Candido, S, Libra, M, Gulino, A, Cancila, V, McCubrey, J A, Montalto, G, Cervello, M
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2016
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5143401/
https://ncbi.nlm.nih.gov/pubmed/27336713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2016.175
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items